Liquid Biopsy for Cancer Diagnostics Market Future Trends Influencing Growth
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Liquid Biopsy For Cancer Diagnostics Market Expected To Scale Between 2026 And 2030?
The liquid biopsy for cancer diagnostics market size has seen rapid growth in recent years. It is anticipated to grow from $10.75 billion in 2025 to $12.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 16.4%. This historical expansion can be attributed to factors such as limitations of tissue biopsy procedures, increasing incidence of lung and breast cancer, early adoption of molecular cancer diagnostics, growing need for early-stage cancer detection, and rising clinical research in oncology diagnostics.
The liquid biopsy for cancer diagnostics market is anticipated to experience substantial growth in the coming years, with projections indicating it will reach $22.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.4%. This expansion over the forecast period is primarily driven by the increased use of liquid biopsy in routine cancer screening, a heightened focus on personalized cancer care, its rising adoption in monitoring treatment responses, growing investments in cancer diagnostics, and its expanding application in gastrointestinal and ovarian cancers. Key trends during this period include the increasing integration of liquid biopsy in diagnosing lung cancer, the rising prevalence of blood-based cancer screening methods, an escalating demand for real-time cancer monitoring, the broadening application of liquid biopsy across multiple cancer types, and a growing clinical preference for minimally invasive diagnostics.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp
Which Factors Are Influencing The Growth Of The Liquid Biopsy For Cancer Diagnostics Market?
The increasing incidence of cancer is anticipated to drive the expansion of the liquid biopsy for cancer diagnostics market in the future. Cancer refers to a broad spectrum of diseases that can manifest in nearly any organ or tissue when abnormal cells proliferate without control, surpassing their usual boundaries, and subsequently spreading to other organs or invading adjacent body parts. The prevalence of cancer underscores the demand for diagnostic procedures like early detection of cancer or tumor recurrence, personalized patient risk assessment, and treatment monitoring, allowing liquid biopsy to reveal the full scope of the disease as tumor cells or their products are shed from all metastatic or primary tumor sites, thereby offering comprehensive, real-time information on tumor cell evolution, therapeutic targets, and mechanisms of resistance to therapy. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported approximately 18.1 million cancer survivors in the United States. This number is projected to climb to 22.5 million by 2032. By 2040, new cancer cases each year are expected to reach 29.9 million, with cancer-related deaths estimated to increase to 15.3 million. Therefore, the rising occurrence of cancer is a key factor fueling the growth of the liquid biopsy for cancer diagnostics market.
How Is The Liquid Biopsy For Cancer Diagnostics Market Categorized Across Its Segment Groups?
The liquid biopsy for cancer diagnostics market covered in this report is segmented –
1) By Type: Product, Services
2) By Sample: Blood, Urine, Saliva
3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers
4) By End-User: Hospitals, Diagnostic Centers, Other End-Users
Subsegments:
1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices
2) By Services: Testing Services, Analytical Services, Bioinformatics Services
Which Trends Are Influencing Demand In The Liquid Biopsy For Cancer Diagnostics Market?
Leading companies in the liquid biopsy market for cancer diagnostics are concentrating their efforts on creating innovative solutions, such as advanced liquid biopsy assays. An advanced liquid biopsy assay is a sophisticated and highly refined diagnostic test that examines various components in a liquid biological sample, like blood or other bodily fluids, to identify and characterize specific biomarkers linked to cancer or other diseases. For instance, in November 2023, Illumina Inc., a US-based global leader in DNA sequencing, announced the release of ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. This is a research assay engineered to enable noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) derived from blood. The TSO 500 ctDNA v2 assay is designed to simplify integration for users and deepen the insights available for cancer research.
Which Firms Are Influencing Competition In The Liquid Biopsy For Cancer Diagnostics Market?
Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC
Get The Full Liquid Biopsy For Cancer Diagnostics Market Report:
Which Region Is The Top Contributor To The Liquid Biopsy For Cancer Diagnostics Market By Share?
North America was the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Liquid Biopsy For Cancer Diagnostics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Liquid Biopsy For Cancer Diagnostics Market 2026, By The Business Research Company
Liquid Biopsy For Cancer Diagnostics Market Report 2026
Biopsy Devices Market Report
https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report
Biopsy Devices Market Report
https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
